OKYO Pharma (Nasdaq:OKYO) - Stock Price, News & Analysis

OKYO Stock Overview

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom.

About the company

OKYO fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Risk Analysis

Negative shareholders equity

Makes less than USD$1m in revenue ($0)

Earnings are forecast to decline by an average of 6.7% per year for the next 3 years

Latest financial reports are more than 6 months old

+ 4 more risks

OKYO Pharma Limited Competitors

Gain Therapeutics

NasdaqGM:GANX

US$52.9m

Genenta Science

NasdaqCM:GNTA

US$56.1m

Eledon Pharmaceuticals

NasdaqCM:ELDN

US$59.3m

ARCA biopharma

NasdaqCM:ABIO

US$50.6m

Price History & Performance

Summary of all time highs, changes and price drops for OKYO Pharma
Historical stock prices
Current Share Price	US$1.50
52 Week High	US$3.07
52 Week Low	US$0.89
Beta	-3.15
1 Month Change	2.04%
3 Month Change	0.67%
1 Year Change	n/a
3 Year Change	-71.86%
5 Year Change	n/a
Change since IPO	-33.50%

Recent updates

Shareholder Returns

	OKYO	US Biotechs	US Market
7D	6.4%	-1.5%	-0.7%
1Y	n/a	0.1%	22.3%

Return vs Industry: Insufficient data to determine how OKYO performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how OKYO performed against the US Market.

Price Volatility

Is OKYO's price volatile compared to industry and market?
OKYO volatility
OKYO Average Weekly Movement	12.5%
Biotechs Industry Average Movement	11.5%
Market Average Movement	6.1%
10% most volatile stocks in US Market	16.7%
10% least volatile stocks in US Market	3.1%

Stable Share Price: OKYO has not had significant price volatility in the past 3 months.

Volatility Over Time: OKYO's weekly volatility has decreased from 18% to 12% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2007	8	Gary Jacob	www.okyopharma.com

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain.

OKYO Pharma Limited Fundamentals Summary

How do OKYO Pharma's earnings and revenue compare to its market cap?
OKYO fundamental statistics
Market cap	US$49.85m
Earnings (TTM)	-US$13.27m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-3.8x

P/E Ratio

Is OKYO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
OKYO income statement (TTM)
Revenue	US$0
Cost of Revenue	US$6.85m
Gross Profit	-US$6.85m
Other Expenses	US$6.42m
Earnings	-US$13.27m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.40
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	-107.9%

How did OKYO perform over the long term?

See historical performance and comparison

OKYO Stock Overview

Rewards

Risk Analysis

OKYO Pharma Limited Competitors

NasdaqGM:GANX

US$52.9m

NasdaqCM:GNTA

US$56.1m

NasdaqCM:ELDN

US$59.3m

NasdaqCM:ABIO

US$50.6m

Price History & Performance

Recent News & Updates

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

Okyo Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

OKYO Pharma Limited Announces Appointment of Scientific Advisory Board

OKYO Pharma Limited Reports Positive Safety and Efficacy Results in Its Phase 2, Randomized, Double-Masted, Placebo-Controlled Trial Evaluating the Safety and Efficacy of OK-101 Ophthalmic Solution in Patients with Dry Eye Disease

OKYO Pharma Limited has filed a Follow-on Equity Offering in the amount of $4 million.

Okyo Pharma Limited Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit

Recent updates

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

Okyo Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

OKYO Pharma Limited Announces Appointment of Scientific Advisory Board

OKYO Pharma Limited Reports Positive Safety and Efficacy Results in Its Phase 2, Randomized, Double-Masted, Placebo-Controlled Trial Evaluating the Safety and Efficacy of OK-101 Ophthalmic Solution in Patients with Dry Eye Disease

OKYO Pharma Limited has filed a Follow-on Equity Offering in the amount of $4 million.

Okyo Pharma Limited Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit

OKYO Pharma Limited, Annual General Meeting, Dec 14, 2023

OKYO Pharma Limited has completed a Follow-on Equity Offering in the amount of $1.6389 million.

Okyo Pharma Limited Announces Filing of an Investigational New Drug (Ind) Application for Ok-101 to Treat Neuropathic Corneal Pain

OKYO Pharma Limited Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease (DED)

OKYO Pharma Limited has completed a Follow-on Equity Offering in the amount of $4.000005 million.

OKYO Pharma Limited has completed a Follow-on Equity Offering in the amount of $4.000005 million.

Okyo Pharma Limited Completes Enrollment in Phase 2 Clinical Trial of Ok-101 to Treat Dry Eye Disease

OKYO Pharma Limited announced delayed 20-F filing

OKYO Pharma Limited Plans to Initiate Phase 2 Trial of Ok-101 in Neuropathic Corneal Pain

OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer, Effective September 1, 2023

New minor risk - Shareholder dilution

OKYO Pharma Limited Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular Ok-101 for Dry Eye Disease

OKYO Pharma's Ordinary Shares of No Par Value, Fully Paid Cancels from Admission to Trading on London Stock Exchange

OKYO Pharma Announces Change of Delisting Date to 22 May 2023

OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease

OKYO Pharma Limited Announces U.S. IND Filing on Ok-101 for the Treatment of Dry Eye Disease

OKYO Pharma Plans Fourth Quarter 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm

OKYO Pharma Limited, Annual General Meeting, Sep 07, 2022

OKYO Pharma Limited announced delayed 20-F filing

OKYO Pharma Limited Announces Successful Completion of A Pre-IND Meeting with the U.S. Food and Drug Administration on the Development of OK-101 to Treat Dry Eye Disease

OKYO Pharma Limited Announces First-in-Class Drug Candidate OK-101 Displaying Both Anti-inflammatory and Ocular Pain-Reducing Potential to Treat Dry Eye Disease

OKYO Pharma Announces Positive Data and Results in an Animal Model Using Topically Administered OK-201 to Treat Neuropathic Ocular Pain

OKYO Pharma Limited Has U.S. Patent Issues Covering its Lipid Conjugated Peptide Analogues for Treating Ocular Pain and Inflammation

Okyo Pharma Limited Announces Filing of A Patent Application Covering the Use of Chemerin and Associated Analogues to Treat “Cytokine Storm” Associated with COVID-19 and ARDS

OKYO Pharma Limited Appoints Gary S. Jacob as Chief Executive Officer